Assignee
PIERIS PHARMACEUTICALS GMBH
DE·35 granted patents·17 pending applications·99 citations·filing 2012–2022
Top patents by PatentIndex Score
52 records- 0193US10857202B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Dec 8, 2020·4 cites·18 claims
- 0292US11382951B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Jul 12, 2022·2 cites·19 claims
- 0392US11345728B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted May 31, 2022·2 cites·14 claims
- 0492US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0591US10618941B2Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given targetPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 14, 2020·6 cites·20 claims
- 0690US10016483B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·20 claims
- 0789US10273275B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 30, 2019·10 cites·20 claims
- 0889US10046027B2Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Aug 14, 2018·8 cites·14 claims
- 0988US10774119B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 15, 2020·3 cites·13 claims
- 1087US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 1187US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 1287US10398754B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Sep 3, 2019·4 cites·19 claims
- 1387US9687524B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Jun 27, 2017·6 cites·7 claims
- 1485US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 1583US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 1683US10232014B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Mar 19, 2019·3 cites·25 claims
- 1783US9572863B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Feb 21, 2017·4 cites·20 claims
- 1882US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 1982US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 2082US9950034B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Apr 24, 2018·3 cites·20 claims
- 2182US9610356B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Apr 4, 2017·7 cites·23 claims
- 2280US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 2379US2023021168A1Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2477US11382963B2Engineered T cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 12, 2022·1 cites·5 claims
- 2575US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 2675US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 2774US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 2872US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 2971US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 3071US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 3168US2022296690A1Engineered t cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 3266US10927154B2Multi-specific polypeptide useful for localized tumor immunomodulationPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Feb 23, 2021·1 cites·6 claims
- 3364US11827681B2Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given targetPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Nov 28, 2023·0 cites·21 claims
- 3463US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 3560US10787491B2Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Sep 29, 2020·0 cites·11 claims
- 3660US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 3759US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 3859US2019015477A1Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 3956US2017066807A1Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 4055US2018311311A1Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 4152US2017369542A1Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding suchPIERIS PHARMACEUTICALS GMBH·Filed 2017·Application pending·0 cites
- 4251US2024166763A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 4351US2024228562A1Novel lipocalin muteins specific for connective tissue growth factor (ctgf)PIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 4451US2024166764A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 4550US2023227568A1Multimeric immunomodulator targeting 4-1bbPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 4650US2023366884A1Biomarker methods and usesPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 4749US9751920B2Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 5, 2017·0 cites·2 claims
- 4847US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 4946US2021246219A1Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 5045US12486330B2Fusion proteins specific for CD137 and GPC3PIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Dec 2, 2025·0 cites·6 claims
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PIERIS PHARMACEUTICALS GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →